Search

everythinglearnresearchcommunity

for

Search:↓

The Brazilian Society of Dermatology agrees that oral isotretinoin is effective for acne and other skin conditions, and it's safe when monitored, but more research is needed on dosing and duration.

Early use of infliximab in severe pediatric Crohn's disease can lead to significant improvement and remission.

Ritlecitinib is effective and safe for long-term treatment of alopecia areata.

Low-dose Buserelin effectively reduces hirsutism with minimal side effects.

Ustekinumab treatment may reveal a genetic tendency for steatocystoma multiplex in psoriasis patients.

A 29-year-old woman with symptoms of both lupus and rheumatoid arthritis improved with specific medications.

A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.

Adalimumab significantly improves quality of life for patients with moderate to severe hidradenitis suppurativa.

Guselkumab effectively reduces fatigue in Psoriatic Arthritis patients over two years.

Ritlecitinib is effective and safe for treating severe alopecia areata, showing significant hair regrowth and improved mental health.

Clofazimine effectively treated ashy dermatosis in a patient.

IL-17 inhibitors are more effective than methotrexate in preventing psoriatic arthritis in psoriasis patients.

Thalidomide works best for skin lupus not helped by antimalarials, but has many side effects; other treatments are less effective, especially if patients also have systemic lupus.

Tirzepatide might help manage PCOS in obese patients but needs more research to confirm safety and effectiveness.

A patient with Crohn's disease grew back their hair after stopping Adalimumab, which had caused hair loss.

LGD1069 effectively prevents breast tumors in mice without toxicity.

Stopping infliximab and using strong topical steroids can regrow hair lost due to psoriasiform alopecia.

Previous alopecia areata treatments do not affect the long-term effectiveness of ritlecitinib.

Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.

Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.

Sirolimus effectively reduces lesions and improves quality of life in Blue Rubber Bleb Nevus Syndrome with manageable side effects.

Acne treatment with isotretinoin increases the presence of p53, a protein, in skin and oil glands, which may help reduce acne severity.

Ritlecitinib is generally safe for alopecia areata patients over 72 months.

Plerixafor may help treat pigmentation disorders by promoting skin repigmentation.

ZD1839 (Iressa) causes skin and hair side effects, treatable with tretinoin cream and minocycline.

Clinicians should consider individual factors and communicate risks and benefits when prescribing ritlecitinib for adolescent alopecia areata.

Delonix polymeric nanoparticles with isotretinoin effectively treat acne by targeting hair follicles and reducing skin irritation.

INTASYL is a promising, adaptable RNAi technology for treating skin cancers.

Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.